Claims for Patent: 6,544,503

Summary for Patent: 6,544,503

Title:	Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
Abstract:	The invention is a process for the preparation of crosslinked water-swellable polymer particles. First, an aqueous polymer solution containing a water-soluble polymer having at least one functional group or charge, is combined with aqueous medium. The aqueous polymer solution is then mixed under moderate agitation with an oil medium and an emulsifier to form an emulsion of droplets of the water-soluble polymer. A crosslinking agent capable of crosslinking the functional groups and/or charges in the water-soluble polymer is then added to the emulsion to form crosslinked water-swellable polymer particles. The invention also includes the particles formed by the process and aqueous dispersions containing the particles which are useful for administering to an individual. The particles of the invention are useful for implantation, soft tissue augmentation, and scaffolding to promote cell growth.
Inventor(s):	Vanderhoff; John W. (Bethlehem, PA), Lu; Cheng Xun (Somerset, NJ), Lee; Clarence C. (Lilburn, GA), Tsai; Chi-Chun (Lawrenceville, GA)
Assignee:	C. R. Bard, Inc. (Murray Hill, NJ) Lehigh University (Bethlehem, PA)
Application Number:	09/563,037
Patent Claims:	1. A method of soft tissue augmentation comprising administering to a patient in need of soft tissue augmentation an aqueous dispersion of crosslinked water-swellable polymer particles in an amount to effectively augment the affected tissue of the patient, wherein the particles are substantially homogeneous in size, wherein the particles are between about 10 micrometers in diameter and about 250 micrometers in diameter, and wherein at least 80% of the particles are spherical. 2. The method of claim 1, wherein the particles contain at least one water-soluble polymer selected from the group consisting of proteins, polysaccharides, peptidoglycans, glycoproteins, proteoglycans, celluloses, teichoic acids, lipopolysaccharides, and synthetic hydrophilic polymers, sodium alginate, poly(N-vinyl pyrrolidone), methyl cellulose, chitin, chitosan, agarose, dextrans, poly(vinyl alcohol), chondroitin sulfate, xanthans, dermatan sulfate, keratin sulfate, amylose, amylopectin, carrageenans, glycogen, starch, heparin sulfate, limit dextians and fragments thereof, emulsan, gellan, curdlan, hyaluronic acid, poly(ethylene oxide), bovine serum albumin, human gamma globulin, and mixtures thereof. 3. The method of claim 1, wherein the particles comprise at least one water-soluble polymer which is a polysaccharide. 4. The method of claim 3, wherein the polysaccharide is selected from the group consisting of hyaluronic acid, sodium alginate, chondroitin sulfate, celluloses, chitin, chitosan, agarose, dextrans, xanthans, dermatan sulfate, amylose, emulsan, gellan, curdlan, amylose, carrageenans, amylopectin, glycogen, starch, heparin sulfate, and limit dextrins or fragments thereof. 5. The method of claim 1, wherein the aqueous dispersion of crosslinked water-swellable polymer particles is administered to a patient in an amount effective to treat a defect selected from the group consisting of urinary incontinence, vesicoureteral reflux, glottic insufficiency, gastroesophageal reflux, and skin defects. 6. The method of claim 1, wherein the particles further comprise a bioactive agent. 7. A method of promoting tissue growth comprising administering to a patient in need of tissue growth an aqueous dispersion of crosslinked water-swellable polymer particles in an amount which provides a scaffold sufficient to promote tissue growth in the patient, wherein the particles are substantially homogeneous in size, wherein the particles are between about 10 micrometers in diameter and about 250 micrometers in diameter, and wherein at least 80% of the particles are spherical. 8. The method of claim 7, wherein the particles contain at least one water-soluble polymer selected from the group consisting of proteins, polysaccharides, peptidoglycans, glycoproteins, proteoglycans, celluloses, teichoic acids, lipopolysaccharides, and synthetic hydrophilic polymers, sodium alginate, poly(N-vinyl pyrrolidone), methyl cellulose, chitin, chitosan, agarose, dextrans, poly(vinyl alcohol), chondroitin sulfate, xanthans, dermatan sulfate, keratin sulfate, amylose, amylopectin, carrageenans, glycogen, starch, heparin sulfate, limit dextrans and fragments thereof, emulsan, gellan, curdlan, hyaluronic acid, poly(ethylene oxide), bovine serum albumin, human gamma globulin, and mixtures thereof. 9. The method of claim 7, wherein the particles comprise at least one water-soluble polymer which is a polysaccharide. 10. The method of claim 9 , wherein the polysaccharide is selected from the group consisting of hyaluronic acid, sodium alginate, chondroitin sulfate, celluloses, chitin, chitosan, agarose, dextrans, xanthans, dermatan sulfate, amylose, emulsan, gellan, curdlan, amylose, carrageenans, amylopectin, glycogen, starch, heparin sulfate, and limit dextrins or fragments thereof. 11. The method of claim 7, wherein the aqueous dispersion of crosslinked water-swellable polymer particles is administered to a patient in an amount effective to promote cell growth of tissue in the breast, lip, penis, bone, cartilage, or tendon. 12. The method of claim 7, wherein the aqueous dispersion of water-swellable polymer particles is administered to a patient in an amount effective to promote wound healing. 13. The method of claim 7, wherein the particles further comprise a bioactive agent. 14. The method of claim 1, wherein the particles contain at least one water-soluble polymer selected from the group consisting of polysaccharides, peptidoglycans, glycoproteins, proteoglycans, celluloses, teichoic acids, lipopolysaccharides, and synthetic hydrophilic polymers, sodium alginate, poly(N-vinyl pyrrolidone), methyl cellulose, chitin, chitosan, agarose, dextrans, poly(vinyl alcohol), chondroitin sulfate, xanthans, dermatan sulfate, amylose, amylopectin, carrageenans, glycogen, starch, heparin sulfate, limit dextrins and fragments thereof, emulsan, gellan, curdlan, hyaluronic acid, poly(ethylene oxide), and mixtures thereof. 15. The method of claim 7, wherein the particles contain at least one water-soluble polymer selected from the group consisting of polysaccharides, peptidoglycans, glycoproteins, proteoglycans, celluloses, teichoic acids, lipopolysaccharides, and synthetic hydrophilic polymers, sodium alginate, poly(N-vinyl pyrrolidone), methyl cellulose, chitin, chitosan, agarose, dextrans, poly(vinyl alcohol), chondroitin sulfate, xanthans, dermatan sulfate, amylose, amylopectin, carrageenans, glycogen, starch, heparin sulfate, limit dextrins and fragments thereof, emulsan, gellan, curdlan, hyaluronic acid, poly(ethylene oxide), and mixtures thereof.

Details for Patent 6,544,503

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2015-06-06
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2015-06-06
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2015-06-06
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2015-06-06
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2015-06-06
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2015-06-06
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	03/17/2000		2015-06-06